Ion Beam Applications SA (0GZK.IL)
| Previous close | 13.04 |
| Open | 13.46 |
| Bid | 13.46 x 0 |
| Ask | 13.98 x 0 |
| Day's range | 13.46 - 13.86 |
| 52-week range | 8.27 - 17.11 |
| Volume | |
| Avg. volume | 12,426 |
| Market cap | 446.894M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.71 |
| Earnings date | 23 May 2024 |
| Forward dividend & yield | 0.21 (2.36%) |
| Ex-dividend date | 29 June 2023 |
| 1y target est | N/A |
GlobeNewswireIBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, US
Louvain-La-Neuve, Belgium, 2 May 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy Center, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, for the installation of a Proteus®ONE1 compact proton therapy system. The contract includes a multi-year operation and maintenance agreement, and it is expected that the center wil
- GlobeNewswire
Iba – Transparency Notification
Louvain-la-Neuve, Belgium, April 11, 2024, 6pm Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007, on disclosure of major holdings, further to the notification received on April 9, 2024. In its notification, Vallcara Limited indicated that following an acquisition, its to
- GlobeNewswire
IBA Reports Full Year 2023 Results
GROUP REVENUES UP 18.7% WITH OTHER ACCELERATORS UP 51.1% REBIT POSITIVE FOR FY23 WITH OTHER ACCELERATORS REBIT ALMOST QUADRUPLING MEDIUM TERM GUIDANCE REITERATED Louvain-la-Neuve, Belgium, 21 March 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2023 financial year. (EUR 000)FY 2023FY 2022VarianceVariance %Total Net Sales428 717361 27067 44718.7% Proton Therapy229 065 218 76110 3044.7% Other Accelerator
